Publications by authors named "Marco Lanza"

Claim this Profile
M
Modulation of NMDA receptor activity by CR4056, an imidazoline-2 receptor ligand with analgesic properties.
Giulia Puja, Gabriele Losi, Lucio Rovati, Marco Lanza, Gianfranco Caselli

Front Pain Res (Lausanne)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent models.
Emanuele Sala, Flora Ferrari, Marco Lanza, Chiara Milia, Chiara Sabatini

Br J Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons.
Vittorio Vellani, Chiara Sabatini, Chiara Milia, Gianfranco Caselli, Marco Lanza

Br J Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of subnanomolar-affinity serotonin 5-HT receptor ligands based on quinoline structures.
Federica Castriconi, Marco Paolino, Giorgio Grisci, Cinzia Maria Francini, Annalisa Reale, Marco Lanza

Medchemcomm· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterisation of CR6086, a potent prostaglandin E receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.
Gianfranco Caselli, Albino Bonazzi, Marco Lanza, Flora Ferrari, Daniele Maggioni

Arthritis Res Ther· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis.
Eleonora Comi, Marco Lanza, Flora Ferrari, Valeria Mauri, Gianfranco Caselli

J Pain Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivalent ligands for the serotonin 5-HT receptor.
Federica Castriconi, Marco Paolino, Alessandro Donati, Germano Giuliani, Maurizio Anzini, Marco Lanza

Medchemcomm· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation.
Giovanni Caprioli, Valerio Mammoli, Massimo Ricciutelli, Gianni Sagratini, Massimo Ubaldi, Marco Lanza

Eur J Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats.
Marco Lanza, Flora Ferrari, Ilaria Menghetti, Dario Tremolada, Gianfranco Caselli

Br J Pharmacol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendrimeric tetravalent ligands for the serotonin-gated ion channel.
Marco Paolino, Laura Mennuni, Germano Giuliani, Maurizio Anzini, Marco Lanza

Chem Commun (Camb)· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold.
Federica Castriconi, Marco Paolino, Germano Giuliani, Maurizio Anzini, Giuseppe Campiani, Marco Lanza

Eur J Med Chem· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
Fabio Del Bello, Eleonora Diamanti, Mario Giannella, Valerio Mammoli, Laura Mattioli, Marco Lanza

ACS Med Chem Lett· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Andrea Cappelli, Monica Manini, Salvatore Valenti, Federica Castriconi, Germano Giuliani, Marco Lanza

Eur J Med Chem· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.
Cristina Meregalli, Cecilia Ceresa, Annalisa Canta, Valentina Alda Carozzi, Alessia Chiorazzi, Marco Lanza

J Pain Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental pharmacology of glucosamine sulfate.
Riccardo Chiusaroli, Tiziana Piepoli, Tiziano Zanelli, Paola Ballanti, Marco Lanza

Int J Rheumatol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.
Flora Ferrari, Simonetta Fiorentino, Laura Mennuni, Paolo Garofalo, Ornella Letari, Marco Lanza

J Pain Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.
Riccardo Chiusaroli, Paolo Garofalo, Stefano Espinoza, Elisa Neri, Gianfranco Caselli, Marco Lanza

Pharmacol Res· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sophie Sarre, Marco Lanza, Francesco Makovec, Roberto Artusi, Gianfranco Caselli

Eur J Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.
Gabriele Losi, Marco Lanza, Francesco Makovec, Roberto Artusi, Gianfranco Caselli

Neuropharmacology· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis